Table 2. Randomized trials of main neoadjuvant chemotherapy in NSCLC.

Study name	Study type	Setting	Number of patients	Disease stage	Drug(s)	Response rate, %	P value/HR (95% CI)	3-yr DFS, %
NATCH	Phase III	Adjuvant/neoadjuvant	624	IA–II	CBDCA-PTX	53.3	0.176/0.92 (0.81–1.04)	38.3
IFCT 0002	Phase III	Neoadjuvant/perioperative	528	I–II	CBDCA-PTX; CDDP-Gem	52.3/49.2	0.63/1.06 (0.84–1.33)	56.1
LU22/NALVT/ EORTC	Phase III	Neoadjuvant	519	I–III	Platinum-based	49	0.86/1.02 (0.80–1.31)	NS
ChEST	Phase III	Neoadjuvant	129	I–IIIA	CBDCA-Gem	35.4	0.03/0.70 (0.50–0.97)	52.9

NSCLC, non-small cell lung cancer; ChEST, chemotherapy in early-stages NSCLC trial; CBDCA, carboplatin; CDDP, cisplatin; CI, confidence interval; CT, chemotherapy; Gem, gemcitabine; HR, hazard ratio; NS, not stated; PTX, paclitaxel; yr, years; NSCLC, non-small cell lung cancer.